Evidence map›Paper›PMID 35013734›Full record

ArticleBiological psychiatry global open science2023

Risk of Death in Individuals Hospitalized for COVID-19 With and Without Psychiatric Disorders: An Observational Multicenter Study in France.

Nicolas Hoertel, Marina Sánchez-Rico, Pedro de la Muela, Miriam Abellán, Carlos Blanco, Marion Leboyer, Céline Cougoule, Erich Gulbins, Johannes Kornhuber, Alexander Carpinteiro and 10 more

Abstract read
In one paragraph

Article in Biological psychiatry global open science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Nicolas HoertelDépartement Médico-Universitaire Psychiatrie et Addictologie, Service de Psychiatrie et Addictologie, Assistance Publique-Hôpitaux de Paris Centre, Hôpital Corentin-Celton, Issy-les-Moulineaux, France.
Marina Sánchez-RicoDépartement Médico-Universitaire Psychiatrie et Addictologie, Service de Psychiatrie et Addictologie, Assistance Publique-Hôpitaux de Paris Centre, Hôpital Corentin-Celton, Issy-les-Moulineaux, France.
Pedro de la MuelaDépartement Médico-Universitaire Psychiatrie et Addictologie, Service de Psychiatrie et Addictologie, Assistance Publique-Hôpitaux de Paris Centre, Hôpital Corentin-Celton, Issy-les-Moulineaux, France.
Miriam AbellánDépartement Médico-Universitaire Psychiatrie et Addictologie, Service de Psychiatrie et Addictologie, Assistance Publique-Hôpitaux de Paris Centre, Hôpital Corentin-Celton, Issy-les-Moulineaux, France.
Carlos BlancoDivision of Epidemiology, Services and Prevention Research, National Institute on Drug Abuse, Bethesda, Maryland.
Marion LeboyerINSERM U955, Neuro-Psychiatrie Translationnelle, Université Paris-Est, Paris, France.
Céline CougouleInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, Toulouse, France.
Erich GulbinsDepartment of Molecular Biology, University Medicine Essen, Essen, Germany.
Johannes KornhuberDepartment of Psychiatry and Psychotherapy, University Hospital, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany.
Alexander CarpinteiroDepartment of Molecular Biology, University Medicine Essen, Essen, Germany.
Katrin Anne BeckerDepartment of Molecular Biology, University Medicine Essen, Essen, Germany.
Raphaël VernetDepartment of Medical Informatics, Biostatistics and Public Health Department, L'Assistance Publique-Hôpitaux de Paris Centre-Université de Paris, Hôpital Européen Georges Pompidou, Paris, France.
Nathanaël BeekerUnité de Recherche clinique, L'Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France.
Antoine NeurazINSERM UMR_S 1138, Cordeliers Research Center, Université de Paris, Paris, France.
Jesús M AlvaradoDepartment of Psychobiology & Behavioural Sciences Methods, Faculty of Psychology, Universidad Complutense de Madrid, Campus de Somosaguas, Pozuelo de Alarcón, Spain.
Juan José Herrera-MoruecoDépartement Médico-Universitaire Psychiatrie et Addictologie, Service de Psychiatrie et Addictologie, Assistance Publique-Hôpitaux de Paris Centre, Hôpital Corentin-Celton, Issy-les-Moulineaux, France.
Guillaume AiragnesDépartement Médico-Universitaire Psychiatrie et Addictologie, Service de Psychiatrie et Addictologie, Assistance Publique-Hôpitaux de Paris Centre, Hôpital Corentin-Celton, Issy-les-Moulineaux, France.
Cédric LemogneDépartement Médico-Universitaire Psychiatrie et Addictologie, L'Assistance Publique-Hôpitaux de Paris, Hôpital Hôtel-Dieu, Université de Paris, Service de Psychiatrie de l'adulte, INSERM, Institut de Psychiatrie et Neurosciences de Paris, Paris, France.
Frédéric LimosinDépartement Médico-Universitaire Psychiatrie et Addictologie, Service de Psychiatrie et Addictologie, Assistance Publique-Hôpitaux de Paris Centre, Hôpital Corentin-Celton, Issy-les-Moulineaux, France.
AP-HP/Université de Paris/Inserm COVID-19 Research Collaboration and the AP-HP COVID CDR Initiative, “Entrepôt de Données de Santé,” AP-HP Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prior research suggests that psychiatric disorders could be linked to increased mortality among patients with COVID-19. However, whether all or specific psychiatric disorders are intrinsic risk factors of death in COVID-19 or whether these associations reflect the greater prevalence of medical risk factors in people with psychiatric disorders has yet to be evaluated. Methods: We performed an observational, multicenter, retrospective cohort study to examine the association between psychiatric disorders and mortality among patients hospitalized for laboratory-confirmed COVID-19 at 36 Greater Paris University hospitals. Results: Of 15,168 adult patients, 857 (5.7%) had an ICD-10 diagnosis of psychiatric disorder. Over a mean follow-up period of 14.6 days (SD = 17.9), 326 of 857 (38.0%) patients with a diagnosis of psychiatric disorder died compared with 1276 of 14,311 (8.9%) patients without such a diagnosis (odds ratio 6.27, 95% CI 5.40-7.28, Conclusions: These findings suggest that the increased risk of COVID-19-related mortality in individuals with psychiatric disorders hospitalized for COVID-19 might be explained by the greater number of medical conditions and the higher prevalence of obesity in this population and not by the underlying psychiatric disease.

Indexed as

AntidepressantsComorbidityCOVID-19Mental disordersMood disordersMortalityObesityPsychiatric disordersRisk of deathSARS-CoV-2

Identifiers

PMID35013734
PMCPMC8730644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.